Novartis, on a roll with newly approved Fabhalta, touts its promise in another rare blood disease
Fierce Pharma
DECEMBER 11, 2023
Without revealing numbers, Novartis said that the APPEAR-C3G phase 3 study of patients with C3 glomerulopathy (C3G) demonstrated that iptacopan provided clinically meaningful and statistically significant reduction in proteinuria (protein in the urine).
154 
Let's personalize your content